AZD8233 (AstraZeneca)
Cardiovascular, Metabolic (PCSK9 target)
Phase 1Partnered
Key Facts
Indication
Cardiovascular, Metabolic (PCSK9 target)
Phase
Phase 1
Status
Partnered
Company
About Silence Therapeutics
Silence Therapeutics is a clinical-stage RNA interference (RNAi) company focused on developing novel siRNA therapeutics. As a pioneer in the field, the company's core technology, mRNAi GOLD™, enables the targeted delivery of siRNAs to hepatocytes in the liver. Its lead asset, zerlasiran (SLN360), is in Phase 2 development for cardiovascular risk reduction, and the company has established significant collaborations with AstraZeneca and Hansoh Pharma to expand its pipeline and validate its platform.
View full company profile